Pacira BioSciences, Inc. (PCRX) stock analysis
Healthcare · Drug Manufacturers - Specialty & Generic
From the 10-K filed 2026-02-26
How it makes money
Pacira earns revenue primarily by selling proprietary non-opioid pain therapies directly to hospitals, ambulatory surgery centers, and physicians.
Sales of the flagship product EXPAREL drive the majority of top-line results, representing 79% of total revenue. ZILRETTA contributes an additional 16% of total revenue following the acquisition of Flexion Therapeutics.
Commercial success relies heavily on securing formulary approvals from hospital pharmacy and therapeutics committees, deploying a trained sales force, and maintaining favorable reimbursement structures such as Medicare payments at average sales price plus 6% in outpatient settings.
What protects it: the moat
Management asserts that patent protection, regulatory exclusivity, and proprietary drug delivery platforms protect its earnings from generic and competitive threats.
The company relies on its DepoFoam and HCAd vector technologies to encapsulate and deliver drugs or genetic medicines over extended periods. However, these technological and legal barriers are subject to ongoing challenges, including active patent litigation lawsuits against competitors seeking to market generic versions of its key products.
What growth costs
The company continuously reinvests significant resources into sales force expansion, manufacturing infrastructure, and clinical pipeline development.
Operating expenses include extensive training for commercial teams, investments in manufacturing capacity enhancements to drive gross margin improvements, and ongoing research and development outlays for pipeline candidates such as the gene therapy PCRX-201.
What could damage it
Adverse changes in hospital formulary adoption or reimbursement policies would directly restrict product utilization and impair overall earnings.
Because hospital pharmacy and therapeutics committees must approve drugs before purchase, budget constraints or formulary restrictions can delay or reduce institutional adoption. If hospital pharmacists perceive acquisition costs as too high relative to pharmacy budgets, utilization drops, directly undermining the primary revenue streams generated by EXPAREL and ZILRETTA.
About Pacira BioSciences, Inc.
Pacira BioSciences, Inc. engages in the development, manufacture, marketing, distribution, and sale of non-opioid pain management and regenerative health solutions to healthcare practitioners in the United States. The company offers EXPAREL, a bupivacaine liposome injectable suspension for postsurgical pain management; ZILRETTA, a triamcinolone acetonide extended-release injectable suspension indicated for the management of osteoarthritis and knee pain; and iovera system, a non-opioid handheld cryoanalgesia device used to deliver controlled doses of cold temperature to targeted nerves to produce neurolytic block that interrupts the pain-transmitting signals of a peripheral nerve. It also develops PCRX-201, a novel gene therapy vector platform enabling local administration of genetic medicines with the potential to treat large prevalent diseases like osteoarthritis. It has a development and commercialization, and supply agreement with Aratana Therapeutics, Inc. for NOCITA, a bupivacaine liposome injectable suspension product for use in animals. The company was formerly known as Pacira Pharmaceuticals, Inc. and changed its name to Pacira BioSciences, Inc. in April 2019. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Brisbane, California.